statementSaid on 2026-11-11
CM383 has started Phase Ib clinical trials for mild cognitive impairment due to Alzheimer's disease and mild Alzheimer's disease, and some brokerages regard it as a potential leading Aβ antibody in China; CM559 has also advanced to Phase I clinical trials.
A statement by post author, said on 2026-11-11. Statements are as reported by the cited publishers — not verified by DecisionGateway.
CM383針對阿爾茨海默病源性輕度認知功能障礙和輕度阿爾茨海默病已開展Ib期臨床,被部分券商視為「潛在中國最領先的Aβ抗體」;CM559(N3pG Aβ抗體)亦已推進至I期臨床。
Discussion
Related claims
LY03017 for psychotic disorders associated with Alzheimer's disease has entered Phase II clinical trials in China and completed first dosing; LY03020, as the world's first TAAR1/5-HT2CR dual-target agonist, also lists psychotic disorders associated with Alzheimer's disease as a target indication.post author · statementThe self-developed SHR-3201 injection has been approved by the National Medical Products Administration to conduct clinical trials, and it is intended for Alzheimer's disease.post author · statementSimcere Pharmaceutical has partnered with Germany's Vivoryon to develop SIM0408 in China, targeting neurotoxic amyloid N3pE, and it has been approved by the CDE to enter clinical trials.post author · statementThree pipelines are currently at the preclinical PCC stage and are progressing as planned.昂利康 · statementCagriSema consists of the long-acting amylin receptor agonist cagrilintide and the GLP-1 receptor agonist semaglutide.界面新闻 · statementAt the investor day, management highlighted AI-driven drug discovery (AIDD) as an emerging structural growth driver.管理層 · statement